BHVN Biohaven Ltd.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
• • New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
• • Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
• • Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
• • Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks

Risk Factors

• • Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
• • Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
• • Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
• • Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
• • Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand

Management Discussion & Analysis

• • No revenue or profitability figures disclosed in the provided text
• • No segment performance or cash flow information reported
• • No management outlook, guidance, or key emerging risks mentioned
• • Text focuses on industry data sources, estimates, and trademark notices

What are the latest BHVN SEC filings in 2026?

Biohaven Ltd. (BHVN) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on July 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BHVN file its most recent 10-K annual report?

Biohaven Ltd. (BHVN) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BHVN 10-Q quarterly reports?

Biohaven Ltd. (BHVN)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every BHVN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BHVN filed recently?

Biohaven Ltd. (BHVN)'s most recent 8-K was filed on July 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BHVN insider trading activity (Form 4)?

SignalX aggregates every BHVN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BHVN file with the SEC?

Biohaven Ltd. (BHVN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BHVN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Biohaven Ltd. (BHVN).

What is BHVN's SEC CIK number?

Biohaven Ltd. (BHVN)'s SEC CIK (Central Index Key) number is 1935979. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1935979 to look up all BHVN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BHVN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Biohaven Ltd. (BHVN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.